Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBIT (2022 - 2025)

Historic EBIT for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to -$78.4 million.

  • Praxis Precision Medicines' EBIT fell 3787.1% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 7870.93%. This contributed to the annual value of -$200.2 million for FY2024, which is 5839.22% down from last year.
  • Latest data reveals that Praxis Precision Medicines reported EBIT of -$78.4 million as of Q3 2025, which was down 3787.1% from -$76.1 million recorded in Q2 2025.
  • Praxis Precision Medicines' EBIT's 5-year high stood at -$25.5 million during Q3 2023, with a 5-year trough of -$78.4 million in Q3 2025.
  • For the 4-year period, Praxis Precision Medicines' EBIT averaged around -$51.4 million, with its median value being -$44.3 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first soared by 4467.46% in 2023, then crashed by 13000.79% in 2024.
  • Over the past 4 years, Praxis Precision Medicines' EBIT (Quarter) stood at -$41.5 million in 2022, then skyrocketed by 32.92% to -$27.8 million in 2023, then tumbled by 130.01% to -$64.0 million in 2024, then fell by 22.52% to -$78.4 million in 2025.
  • Its last three reported values are -$78.4 million in Q3 2025, -$76.1 million for Q2 2025, and -$74.7 million during Q1 2025.